1887

Abstract

It has been previously reported that transient corticosteroid immune suppression of ponies experimentally infected with a highly neutralization resistant envelope variant of equine infectious anemia virus (EIAV), designated EIAV, resulted in the appearance of type-specific serum antibodies to the infecting EIAV virus. The current study was designed to determine if this induction of serum neutralizing antibodies was associated with changes in the specificity of envelope determinants targeted by serum antibodies or caused by changes in the nature of the antibodies targeted to previously defined surface envelope gp90 V3 and V4 neutralization determinants. To address this question, the envelope determinants of neutralization by post-immune suppression serum were mapped. The results demonstrated that the neutralization sensitivity to post-immune suppression serum antibodies mapped specifically to the surface envelope gp90 V3 and V4 domains, individually or in combination. Thus, these data indicate that the development of serum neutralizing antibodies to the resistant EIAV was due to an enhancement of host antibody responses caused by transient immune suppression and the associated increase in virus replication.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80374-0
2005-01-01
2019-11-14
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/1/vir860139.html?itemId=/content/journal/jgv/10.1099/vir.0.80374-0&mimeType=html&fmt=ahah

References

  1. Back, N. K., Smit, L., De Jong, J. J., Keulen, W., Schutten, M., Goudsmit, J. & Tersmette, M. ( 1994; ). An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199, 431–438.[CrossRef]
    [Google Scholar]
  2. Ball, J. M., Rushlow, K. E., Issel, C. J. & Montelaro, R. C. ( 1992; ). Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies. J Virol 66, 732–742.
    [Google Scholar]
  3. Chen, M., Shi, C., Kalia, V., Tencza, S. B., Montelaro, R. C. & Gupta, P. ( 2001; ). HIV gp120 V1/V2 and C2-V3 domains glycoprotein compatibility is required for viral replication. Virus Res 79, 91–101.[CrossRef]
    [Google Scholar]
  4. Cheng-Mayer, C., Brown, A., Harouse, J., Luciw, P. A. & Mayer, A. J. ( 1999; ). Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J Virol 73, 5294–5300.
    [Google Scholar]
  5. Craigo, J. K., Leroux, C., Howe, L., Steckbeck, J. D., Cook, S. J., Issel, C. J. & Montelaro, R. C. ( 2002; ). Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication. J Gen Virol 83, 1353–1359.
    [Google Scholar]
  6. Fazekas de, St. Groth S. & Webster, R. G. ( 1966; ). Disquisitions of original antigenic sin. I. Evidence in man. J Exp Med 124, 331–345.[CrossRef]
    [Google Scholar]
  7. Good, M. F., Zevering, Y., Currier, J. & Bilsborough, J. ( 1993; ). ‘Original antigenic sin’, T cell memory, and malaria sporozoite immunity: an hypothesis for immune evasion. Parasite Immunol 15, 187–193.[CrossRef]
    [Google Scholar]
  8. Grund, C. H., Lechman, E. R., Pezzuolo, N. A., Issel, C. J. & Montelaro, R. C. ( 1996; ). Fine specificity of equine infectious anaemia virus gp90-specific antibodies associated with protective and enhancing immune responses in experimentally infected and immunized ponies. J Gen Virol 77, 435–442.[CrossRef]
    [Google Scholar]
  9. Hammond, S. A., Cook, S. J., Lichtenstein, D. L., Issel, C. J. & Montelaro, R. C. ( 1997; ). Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol 71, 3840–3852.
    [Google Scholar]
  10. Hammond, S. A., Raabe, M. L., Issel, C. J. & Montelaro, R. C. ( 1999; ). Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus. Virology 262, 416–430.[CrossRef]
    [Google Scholar]
  11. Hammond, S. A., Li, F., McKeon, B. M., Sr Cook, S. J., Issel, C. J. & Montelaro, R. C. ( 2000; ). Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus. J Virol 74, 5968–5981.[CrossRef]
    [Google Scholar]
  12. Harrold, S. M., Cook, S. J., Cook, R. F., Rushlow, K. E., Issel, C. J. & Montelaro, R. C. ( 2000; ). Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J Virol 74, 3112–3121.[CrossRef]
    [Google Scholar]
  13. Howe, L., Leroux, C., Issel, C. J. & Montelaro, R. C. ( 2002; ). Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype. J Virol 76, 10588–10597.[CrossRef]
    [Google Scholar]
  14. Hussain, K. A., Issel, C. J., Schnorr, K. L., Rwambo, P. M. & Montelaro, R. C. ( 1987; ). Antigenic analysis of equine infectious anemia virus (EIAV) variants by using monoclonal antibodies: epitopes of glycoprotein gp90 of EIAV stimulate neutralizing antibodies. J Virol 61, 2956–2961.
    [Google Scholar]
  15. Hussain, K. A., Issel, C. J., Schnorr, K. L., Rwambo, P. M., West, M. & Montelaro, R. C. ( 1988; ). Antigenic mapping of the envelope proteins of equine infectious anemia virus: identification of a neutralization domain and a conserved region on glycoprotein 90. Arch Virol 98, 213–224.[CrossRef]
    [Google Scholar]
  16. Issel, C. J., Adams, W. V., Jr, Meek, L. & Ochoa, R. ( 1982; ). Transmission of equine infectious anemia virus from horses without clinical signs of disease. J Am Vet Med Assoc 180, 272–275.
    [Google Scholar]
  17. Johnson, W. E. & Desrosiers, R. C. ( 2002; ). Viral persistance: HIV's strategies of immune system evasion. Annu Rev Med 53, 499–518.[CrossRef]
    [Google Scholar]
  18. Klenerman, P. & Zinkernagel, R. M. ( 1998; ). Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 394, 482–485.[CrossRef]
    [Google Scholar]
  19. Kohler, H., Muller, S. & Nara, P. L. ( 1994; ). Deceptive imprinting in the immune response against HIV-1. Immunol Today 15, 475–478.[CrossRef]
    [Google Scholar]
  20. Kono, Y., Hirasawa, K., Fukunaga, Y. & Taniguchi, T. ( 1976; ). Recrudescence of equine infectious anemia by treatment with immunosuppressive drugs. Natl Inst Anim Health Q (Tokyo) 16, 8–15.
    [Google Scholar]
  21. Kundu, S. K., Dupuis, M., Sette, A., Celis, E., Dorner, F., Eibl, M. & Merigan, T. C. ( 1998; ). Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization. AIDS Res Hum Retrovir 14, 1669–1678.[CrossRef]
    [Google Scholar]
  22. Leroux, C., Issel, C. J. & Montelaro, R. C. ( 1997; ). Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J Virol 71, 9627–9639.
    [Google Scholar]
  23. Leroux, C., Craigo, J. K., Issel, C. J. & Montelaro, R. C. ( 2001; ). Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies. J Virol 75, 4570–4583.[CrossRef]
    [Google Scholar]
  24. Li, F., Craigo, J. K., Howe, L., Steckbeck, J. D., Cook, S., Issel, C. & Montelaro, R. C. ( 2003; ). A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J Virol 77, 7244–7253.[CrossRef]
    [Google Scholar]
  25. Lichtenstein, D. L., Issel, C. J. & Montelaro, R. C. ( 1996; ). Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus. J Virol 70, 3346–3354.
    [Google Scholar]
  26. Locher, C. P., Grant, R. M., Collisson, E. A., Reyes-Teran, G., Elbeik, T., Kahn, J. O. & Levy, J. A. ( 1999; ). Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res Hum Retroviruses 15, 1685–1689.[CrossRef]
    [Google Scholar]
  27. Lue, J., Hsu, M., Yang, D., Marx, P., Chen, Z. & Cheng-Mayer, C. ( 2002; ). Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. J Virol 76, 10299–10306.[CrossRef]
    [Google Scholar]
  28. Ly, A. & Stamatatos, L. ( 2000; ). V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J Virol 74, 6769–6776.[CrossRef]
    [Google Scholar]
  29. Malenbaum, S. E., Yang, D., Cavacini, L., Posner, M., Robinson, J. & Cheng-Mayer, C. ( 2000; ). The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J Virol 74, 11008–11016.[CrossRef]
    [Google Scholar]
  30. McGuire, T. C., Fraser, D. G. & Mealey, R. H. ( 2002; ). Cytotoxic T lymphocytes and neutralizing antibody in the control of equine infectious anemia virus. Viral Immunol 15, 521–531.[CrossRef]
    [Google Scholar]
  31. Mealey, R. H., Fraser, D. G., Oaks, J. L., Cantor, G. H. & McGuire, T. C. ( 2001; ). Immune reconstitution prevents continuous equine infectious anemia virus replication in an Arabian foal with severe combined immunodeficiency: lessons for control of lentiviruses. Clin Immunol 101, 237–247.[CrossRef]
    [Google Scholar]
  32. Mealey, R. H., Zhang, B., Leib, S. R., Littke, M. H. & McGuire, T. C. ( 2003; ). Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus. Virology 313, 537–552.[CrossRef]
    [Google Scholar]
  33. Mongkolsapaya, J., Dejnirattisai, W., Xu, X. N. & 11 other authors ( 2003; ). Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9, 921–927.[CrossRef]
    [Google Scholar]
  34. Montefiori, D. C., Hill, T. S., Vo, H. T., Walker, B. D. & Rosenberg, E. S. ( 2001; ). Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol 75, 10200–10207.[CrossRef]
    [Google Scholar]
  35. Montelaro, R. C., Parekh, B., Orrego, A. & Issel, C. J. ( 1984; ). Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus. J Biol Chem 259, 10539–10544.
    [Google Scholar]
  36. Montelaro, R., Ball, J. M. & Rushlow, K. ( 1993; ). Equine Retroviruses. In The Retroviridae, pp. 257–360. Edited by J. A. Levy. New York: Plenum.
  37. Montelaro, R. C., Grund, C., Raabe, M., Woodson, B., Cook, R. F., Cook, S. & Issel, C. J. ( 1996; ). Characterization of protective and enhancing immune responses to equine infectious anemia virus resulting from experimental vaccines. AIDS Res Hum Retroviruses 12, 413–415.[CrossRef]
    [Google Scholar]
  38. Montelaro, R. C., Cole, K. S. & Hammond, S. A. ( 1998; ). Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development. AIDS Res Hum Retroviruses 14, S255–S259.[CrossRef]
    [Google Scholar]
  39. Nara, P. L. & Garrity, R. ( 1998; ). Deceptive imprinting: a cosmopolitan strategy for complicating vaccination. Vaccine 16, 1780–1787.[CrossRef]
    [Google Scholar]
  40. Ortiz, G. M., Nixon, D. F., Trkola, A. & 16 other authors ( 1999; ). HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 104, R13–18.[CrossRef]
    [Google Scholar]
  41. Ortiz, G. M., Wellons, M., Brancato, J. & 9 other authors ( 2001; ). Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A 98, 13288–13293.[CrossRef]
    [Google Scholar]
  42. Payne, S. L., Fang, F. D., Liu, C. P., Dhruva, B. R., Rwambo, P., Issel, C. J. & Montelaro, R. C. ( 1987; ). Antigenic variation and lentivirus persistence: variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV. Virology 161, 321–331.[CrossRef]
    [Google Scholar]
  43. Perryman, L. E., O'Rourke, K. I. & McGuire, T. C. ( 1988; ). Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection. J Virol 62, 3073–3076.
    [Google Scholar]
  44. Polzer, S., Dittmar, M. T., Schmitz, H. & Schreiber, M. ( 2002; ). The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 304, 70–80.[CrossRef]
    [Google Scholar]
  45. Quinones-Kochs, M. I., Buonocore, L. & Rose, J. K. ( 2002; ). Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J Virol 76, 4199–4211.[CrossRef]
    [Google Scholar]
  46. Rwambo, P. M., Issel, C. J., Adams, W. V., Jr, Hussain, K. A., Miller, M. & Montelaro, R. C. ( 1990a; ). Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection. Arch Virol 111, 199–212.[CrossRef]
    [Google Scholar]
  47. Rwambo, P. M., Issel, C. J., Hussain, K. A. & Montelaro, R. C. ( 1990b; ). In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV). Arch Virol 111, 275–280.[CrossRef]
    [Google Scholar]
  48. Singh, R. A., Rodgers, J. R. & Barry, M. A. ( 2002; ). The role of T cell antagonism and original antigenic sin in genetic immunization. J Immunol 169, 6779–6786.[CrossRef]
    [Google Scholar]
  49. Tschetter, J. R., Byrne, K. M., Perryman, L. E. & McGuire, T. C. ( 1997; ). Control of equine infectious anemia virus is not dependent on ADCC mediating antibodies. Virology 230, 275–280.[CrossRef]
    [Google Scholar]
  50. Tsuchiya, H., Furukawa, M., Matsui, M., Katsuki, K. & Inouye, S. ( 2000; ). ‘Original antigenic sin’ phenomenon in neutralizing antibody responses in children with enterovirus meningitis. J Clin Virol 19, 205–207.[CrossRef]
    [Google Scholar]
  51. Tumas, D. B., Hines, M. T., Perryman, L. E., Davis, W. C. & McGuire, T. C. ( 1994; ). Corticosteroid immunosuppression and monoclonal antibody-mediated CD5+ T lymphocyte depletion in normal and equine infectious anaemia virus-carrier horses. J Gen Virol 75, 959–968.[CrossRef]
    [Google Scholar]
  52. Verschoor, E. J., Davis, D., van Gils, M. & 9 other authors ( 1999; ). Efforts to broaden HIV-1-specific immunity by boosting with heterologous peptides or envelope protein and the influence of prior exposure to virus. J Med Primatol 28, 224–232.[CrossRef]
    [Google Scholar]
  53. Zhang, W., Lonning, S. M. & McGuire, T. C. ( 1998; ). Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection. J Virol 72, 9612–9620.
    [Google Scholar]
  54. Zheng, Y. H., Nakaya, T., Sentsui, H., Kameoka, M., Kishi, M., Hagiwara, K., Takahashi, H., Kono, Y. & Ikuta, K. ( 1997; ). Insertions, duplications and substitutions in restricted gp90 regions of equine infectious anaemia virus during febrile episodes in an experimentally infected horse. J Gen Virol 78, 807–820.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80374-0
Loading
/content/journal/jgv/10.1099/vir.0.80374-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error